Global Blood gains on 90-day sickle cell data

Global Blood Therapeutics Inc. (NASDAQ:GBT) gained $2 to $24.15 on Friday after newly presented 90-day data showed sickle disease candidate GBT440 led to durable reductions in hemolysis in an

Read the full 294 word article

User Sign In